@article {7527,
	title = {Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer},
	journal = {OncoTargets and Therapy},
	volume = {7},
	year = {2014},
	note = {Cited By :3Export Date: 21 February 2017},
	month = {2014},
	pages = {1837 - 1845},
	abstract = {Angiogenesis has been implicated in ovarian cancer pathogenesis. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been incorporated in ovarian cancer treatment in combination with chemotherapy both in a frontline setting and in disease recurrence. However, resistance eventually develops and treatment with bevacizumab is associated with increased risk for toxicities such as thromboembolic and hemorrhagic events, gastrointestinal perforation, and impaired wound healing, suggesting the need for new therapeutic approaches. Targeting of the angiopoietins/Tie2 pathway has gained accumulating interest during the last few years as a strategy to overcome bevacizumab resistance and toxicities. Trebananib is a first-in-class peptibody that inhibits angiopoietin 1 and 2 interaction with their receptor Tie2. The molecular profile of this agent, the preclinical data, and clinical studies demonstrating its efficacy in ovarian cancer are discussed in this review. {\textcopyright} 2014 Liontos et al.},
	keywords = {Angiopoietins, Ovarian cancer, Trebananib},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84908222420\&doi=10.2147\%2fOTT.S65522\&partnerID=40\&md5=9aaa2781140a25b0fe2d5d53ac3263b5},
	author = {Liontos, M. and Lykka, M. and Dimopoulos, M.-A. and Bamias, A.}
}
